Post-Approval Patent Strategy: How to Protect Your Drug from Regulatory and IP Risk After Approval
Every time a pharmaceutical company changes something about an approved drug, it opens two doors simultaneously. The first leads to […]
Pharma Patent Strategy: How to Defend Exclusivity Without Getting Sued
The pharmaceutical industry has a math problem. A blockbuster drug throws off cash at a rate that makes any other
Pharma Patent Strategy: How to Defend Exclusivity Without Getting Sued Read Post »
From Humira to Keytruda: The Blueprint for Surviving the Composition of Matter Cliff
A composition of matter patent is the only piece of pharmaceutical intellectual property that a generic or biosimilar manufacturer cannot
From Humira to Keytruda: The Blueprint for Surviving the Composition of Matter Cliff Read Post »
Method-of-Use Patents: The Hidden Lever Rewriting Pharma’s Patent Cliff Math
The composition-of-matter patent is the loudest piece of intellectual property a pharmaceutical company owns. It is also, increasingly, the least
Method-of-Use Patents: The Hidden Lever Rewriting Pharma’s Patent Cliff Math Read Post »
The Patent Dance Decoded: How Biosimilar Developers Win or Lose Before Litigation Starts
The Biologics Price Competition and Innovation Act turned fifteen years old in March, and the procedural ritual it created keeps
The Patent Dance Decoded: How Biosimilar Developers Win or Lose Before Litigation Starts Read Post »
How NLP and AI Predict Drug Patent Expiration and Litigation Risk Before Your Competitors Do
The pharmaceutical industry has always run on information asymmetry. The company that knows, six months before its competitors, that a
Formulation Forensics: How to Reverse-Engineer Blockbuster Drug Patents for a Competitive Design-Around
A practitioner’s guide for IP teams, generic manufacturers, and pharmaceutical investors who need to decode what a competitor’s formulation patent
How to Beat a Patent Thicket: The 505(b)(2) and Complex Generic Playbook
There is a moment, familiar to every generic drug executive, when a promising target drug goes from ‘opportunity’ to ‘nightmare.’
How to Beat a Patent Thicket: The 505(b)(2) and Complex Generic Playbook Read Post »
Patent Risk to Board Metrics: How Pharma Leaders Translate IP Litigation Into Governance
The call came on a Tuesday morning. A general counsel at a mid-sized specialty pharma company had just received a
Patent Risk to Board Metrics: How Pharma Leaders Translate IP Litigation Into Governance Read Post »
